BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 16350675)

  • 1. N-terminal probrain natriuretic peptide as a predictor of short-term outcomes in acute myocardial infarction.
    Puri A; Narain VS; Mehrotra S; Dwivedi SK; Saran RK; Puri VK
    Indian Heart J; 2005; 57(4):304-10. PubMed ID: 16350675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.
    Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ;
    Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction.
    Squire IB; O'Brien RJ; Demme B; Davies JE; Ng LL
    Clin Sci (Lond); 2004 Sep; 107(3):309-16. PubMed ID: 15182235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal probrain natriuretic peptide predicts adverse outcomes in acute-myocardial infarction even with preserved left ventricular ejection fraction.
    Puri A; Narain VS; Mehrotra S; Dwivedi SK; Saran RK; Puri VK
    Indian Heart J; 2006; 58(2):138-43. PubMed ID: 18989058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study.
    Dhillon OS; Khan SQ; Narayan HK; Ng KH; Struck J; Quinn PA; Morgenthaler NG; Squire IB; Davies JE; Bergmann A; Ng LL
    J Am Coll Cardiol; 2010 Jul; 56(2):125-33. PubMed ID: 20620726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
    Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
    Heeschen C; Hamm CW; Mitrovic V; Lantelme NH; White HD;
    Circulation; 2004 Nov; 110(20):3206-12. PubMed ID: 15533869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
    J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.
    Mega JL; Morrow DA; De Lemos JA; Sabatine MS; Murphy SA; Rifai N; Gibson CM; Antman EM; Braunwald E
    J Am Coll Cardiol; 2004 Jul; 44(2):335-9. PubMed ID: 15261928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes.
    Bazzino O; Fuselli JJ; Botto F; Perez De Arenaza D; Bahit C; Dadone J;
    Eur Heart J; 2004 May; 25(10):859-66. PubMed ID: 15140534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.
    Richards AM; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton C; Turner J; Crozier IG; Yandle TG
    Circulation; 2003 Jun; 107(22):2786-92. PubMed ID: 12771003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
    Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
    Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprocedural hyperglycemia in ST elevation myocardial infarction submitted to percutaneous coronary intervention: a prognostic indicator and a marker of metabolic derangement.
    Lazzeri C; Chiostri M; Sori A; Valente S; Gensini GF
    J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):7-13. PubMed ID: 19829142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.
    Westerhout CM; Fu Y; Lauer MS; James S; Armstrong PW; Al-Hattab E; Califf RM; Simoons ML; Wallentin L; Boersma E;
    J Am Coll Cardiol; 2006 Sep; 48(5):939-47. PubMed ID: 16949483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short term prognostic role of NT-proBNP in patients after myocardial infarction.
    Coppola G; Corrado E; Augugliaro S; Mulè MC; Rotolo A; Ciaramitaro G; Farinella M; Evola G; Novo G; Evola S; Andolina G; Caruso M; Cospite V; Vitale F; Hoffmann E; Assennato P; Novo S
    Minerva Cardioangiol; 2009 Feb; 57(1):13-21. PubMed ID: 19202516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).
    James SK; Lindahl B; Timmer JR; Ottervanger JP; Siegbahn A; Stridsberg M; Armstrong P; Califf R; Wallentin L; Simoons ML
    Am J Cardiol; 2006 Jan; 97(2):167-72. PubMed ID: 16442356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.
    Weber M; Bazzino O; Navarro Estrada JL; Fuselli JJ; Botto F; Perez de Arenaza D; Möllmann H; Nef HN; Elsässer A; Hamm CW
    J Am Coll Cardiol; 2008 Mar; 51(12):1188-95. PubMed ID: 18355657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy.
    Squire IB; Ørn S; Ng LL; Manhenke C; Shipley L; Aarsland T; Dickstein K
    J Card Fail; 2005 Sep; 11(7):492-7. PubMed ID: 16198243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients.
    Wang AY; Lam CW; Yu CM; Wang M; Chan IH; Zhang Y; Lui SF; Sanderson JE
    J Am Soc Nephrol; 2007 Jan; 18(1):321-30. PubMed ID: 17167121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.